Drugs / Sulindac 150 MG
last change Mar 2019 re-read 2 minutes ago

Sulindac 150 MG

Developed for
classic familial adenomatous polyposis
Investigated by
Cancer Prevention Pharmaceuticals, Inc.

Trials 1 · a red edge is where a trial was stopped

20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT01483144 Oct 2013 → Nov 2018 classic familial adenomatous polyposis Cancer Prevention Pharmaceuticals, Inc. Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Sulindac 150 MG ClinicalTrials.gov intervention name — accepted as the source's own label NCT01483144
Route Oral “Sulindac \[one tablet orally once a day\]” NCT01483144